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As the novel coronavirus continues to spread globally, efforts are 
being accelerated to identify effective preventive and therapeutic 
measures to mitigate the impact of COVID‐19.[1] As of 10 June 2020, 
South Africa (SA) had recorded a total of 55 421 cases and 1 210 
fatalities, making it the most affected country in Africa.[2] With no 
licensed vaccine or definitive treatment, the clinical management of 
COVID-19 has been mostly supportive care.[3] Convalescent plasma 
is being considered as one of the potential therapies for reducing the 
morbidity and mortality burdens of the disease, particularly among 
those who are severely or critically ill.[1,3]
Objectives
To highlight and contextualise the findings of a recently published 
Cochrane rapid review by Valk et al.[1] that evaluated the effectiveness 
and safety of convalescent plasma or hyperimmune immunoglobulin 
transfusion in the treatment of people with COVID‐19. 
Intervention and methods
The authors considered studies that evaluated the effects of 
convalescent plasma or hyperimmune immunoglobulin on people 
diagnosed with COVID-19 in their review, irrespective of disease 
severity, age, gender or ethnicity. Although theirs was a rapid review, 
the authors followed the standard Cochrane systematic review 
methodology and performed all steps of study screening and selection 
in duplicate. They searched various research databases and trial 
registries for both completed and ongoing studies. They combined 
terms for the novel coronavirus (e.g. SARS-CoV-2 and nCoV‐2019), 
the disease (e.g. COVID-19 and COVID19), convalescent plasma and 
hyperimmune immunoglobulin.
Results
The review identified 8 studies, with a total of 32 participants who 
were critically ill. All of these participants received only convalescent 
plasma at varying doses. The studies included 7 case series and 
1 prospectively planned, single‐arm intervention study. None was a 
randomised controlled trial (RCT). In addition, the authors identified 
48 ongoing studies evaluating convalescent plasma (47 studies)  or 
hyperimmune immunoglobulin (1 study) in COVID-19 patients, of 
which 22 are RCTs.
From the results of this review, the authors reported that there was 
clinical improvement in all participants, and no participant died after 
37 days of follow-up. Four of the participants experienced undesirable 
effects: 1 had moderate fever (39ºC), and 3 had anaphylactic shock 
after receiving convalescent plasma. The authors judged these studies 
to be of low quality, with small numbers of participants; inconsistency 
of outcome measures; variation in outcome reporting across studies; 
and differences in disease severity, comorbidities, and previous or 
concurrent treatments across participants.
Conclusions
This Cochrane review has found limited and low‐certainty evidence 
on the effectiveness and safety of convalescent plasma for the 
treatment of COVID‐19. To mitigate the morbidity and mortality of 
COVID-19, convalescent plasma may offer a ray of hope to SA. There 
is therefore a need for further investigation to ascertain not only the 
effectiveness and safety but the practicality of this therapeutic option 
within the capacity of SA’s local blood transfusion services.
Implications for practice
Overall, these findings represent very limited and low‐certainty 
evidence on the effectiveness and safety of convalescent plasma 
therapy for people with COVID‐19. In spite of these limitations, 
convalescent plasma transfusion may offer a therapeutic ray of 
hope for SA’s fight against COVID-19, given its previous successes 
in the treatment of similar respiratory diseases such as Middle East 
respiratory syndrome (MERS), severe acute respiratory syndrome 
(SARS) and pandemic influenza A (H1N1).[4] As lockdowns and 
movement restrictions are being eased in SA, the threats posed to the 
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country’s already strained health system by the possibility of further 
spread of the virus are dire.[5] The country must therefore brace 
for these threats by exploring potential therapeutic options such 
as convalescent plasma transfusion to mitigate the morbidity and 
number of deaths at the peak of the outbreak.
There is a need for further investigation of the benefits, safety and 
practicality of the therapy for COVID-19 patients in well-designed 
studies to provide more evidence that will guide clinical decisions 
in the SA context. Although convalescent plasma is generally 
thought to be safe and well tolerated, adverse events can occur. [6] 
As with other types of blood components, the adverse events 
associated with plasma transfusions are well characterised, including 
transfusion‐related acute lung injury and transfusion‐associated 
circulatory overload, which are leading causes of transfusion‐related 
mortality. [1] Like other blood components, the use of convalescent 
plasma or hyperimmune immunoglobulin requires functional blood 
transfusion resources and services. During the 2014 Ebola outbreak, 
attempts to use convalescent plasma revealed the challenges faced by 
African countries in ensuring transfusion safety.[7]
Compared with the rest of Africa, SA has relatively well developed 
national blood transfusion policies and services.[7] These existing 
resources and infrastructure can be leveraged for investigating 
and implementing plasma transfusion for COVID-19. There are 
indications that this is already beginning to happen, with the South 
African National Blood Service currently planning to investigate and 
use the plasma for the treatment of COVID-19 patients locally. [8] 
However, doing so may have limited feasibility in provinces where 
blood transfusion services are less developed, with limited capacity 
to meet routine blood transfusion demands. Building local capacity 
of blood transfusion services in donor recruitment, blood collection, 
adequate blood screening and transfusion safety monitoring will 
therefore be crucial for the safe and rational use of convalescent 
plasma in the country.[7]
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